{"id":"W2793000264","doi":"10.1001/jamaoncol.2017.5808","title":"Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Active Biotech; Astellas Pharma; Eisai; Ipsen; Clovis Oncology; Advanced Accelerator Applications; Endocyte; Gilead Sciences; Genentech; Valeant Pharmaceuticals International; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Prostate cancer; Enzalutamide; Oncology; Internal medicine; Progression-free survival; Clinical endpoint; Clinical trial; Placebo; Discontinuation; Cancer; Chemotherapy; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05260551,0.0007672339,0.0012026,0.0006957123,0.0001933353,0.000971199,0.0006726409,0.0007721691,0.001052786],"category_scores_gemma":[0.03267132,0.0002374373,0.002690164,0.0009053189,0.0009236056,0.0006317614,0.0007054244,0.001502602,0.00008864301],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005158532,"about_ca_system_score_gemma":0.001757961,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006840244,"about_ca_topic_score_gemma":0.002130135,"domain_scores_codex":[0.9672454,0.02967245,0.0009756847,0.0006869927,0.001271076,0.0001483455],"domain_scores_gemma":[0.9687482,0.02098739,0.007464055,0.001420385,0.0008715648,0.0005083267],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4216281,0.002944798,0.2955826,0.01009784,0.02558711,0.0002696026,0.0003706085,0.02658209,0.01256034,0.002490853,0.004656561,0.1972295],"study_design_scores_gemma":[0.05637923,0.162119,0.697304,0.001882366,0.01359516,0.0007854992,0.0001913363,0.03428099,0.01288771,0.005246256,0.0150787,0.0002497109],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9319627,0.0500894,0.008968364,0.001662227,0.0003441382,0.002037412,0.001999066,0.0000861322,0.002850597],"genre_scores_gemma":[0.9915621,0.002162511,0.003657436,0.0006030061,0.0002256206,0.0008119056,0.0006196068,0.00001097621,0.0003467733],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05260551,"threshold_uncertainty_score":0.2782078,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04999381704449428,"score_gpt":0.4252381961655681,"score_spread":0.3752443791210738,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}